Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2008

01-12-2008 | Clinical Trial

Paget’s disease of the breast: the experience of the European institute of oncology and review of the literature

Authors: Mujgan Caliskan, Giovanna Gatti, Irina Sosnovskikh, Nicole Rotmensz, Edoardo Botteri, Simona Musmeci, Gabriela Rosali dos Santos, Giuseppe Viale, Alberto Luini

Published in: Breast Cancer Research and Treatment | Issue 3/2008

Login to get access

Abstract

Background Paget’s disease of the breast is an uncommon presentation of breast malignancy, accounting for 1–3% of all the breast tumors and presents in different histopathologic patterns: in association with an underlying invasive or non invasive carcinoma, or without any underlying neoplasia. In the literature, different methods are used for the treatment. Mastectomy with or without axillary dissection has been considered as the standard treatment procedure for many years. Several studies have already shown that breast conservation with radiation therapy is an oncologically safe option. Regarding the axillary approach, several studies have documented the presence of positive sentinel lymph node even in Paget’s disease alone. The objective of this study was to retrospectively analyze outcome of patients affected by Paget’s breast disease and to define our institutional experience. Patients and methods Between May 1996 and February 2003, 114 patients with confirmed Paget’s disease of the breast were retrieved and underwent surgery at the European Institute of Oncology of Milan, Italy. The median age of the patients was 54 years at the time of the diagnosis. In our study, the histopathological examination of the operated specimen revealed one hundred seven patients with Paget’s disease associated with an underlying invasive or non invasive carcinoma, and seven patients without underlying carcinoma. Patients underwent either conservative breast surgery or mastectomy, with or without sentinel lymph node biopsy and/or axillary surgery. Each patient was evaluated after surgery at a multidisciplinary meeting to selecting systemic therapy. Results Seven patients had “pure” Paget’s disease of the breast and one hundred seven had the disease associated with an underlying carcinoma. As surgical techniques 71 mastectomies and 43 breast conserving surgeries have been performed. Complete axillary dissection was done in patients with clinically positive lymph node and/or sentinel lymph node biopsy positive. Sentinel lymph node biopsy was performed in nineteen patients with invasive component and five were positive and underwent axillary dissection. Eleven sentinel lymph node biopsies were done in patients with non invasive component and none of them was positive. Adjuvant systemic therapies were based on the final tumor, node and metastasis stage: thirty patients received adjuvant chemotherapy alone, fourteen received endocrine treatment alone, twenty-six patients were evaluated to receive both chemo and endocrine therapy. The median duration of follow up was 73 months and was updated in the last 6 months. Five patients developed local recurrence, one had regional recurrence, another two had loco-regional recurrences and fourteen had distant metastasis as a first event. Malignancy-related deaths were censored in the statistical analyses cancer for and due to another tumor in eleven patients. Additionally, deaths were not related to malignancy totally in thirteen patients. Conclusions Screening examination and imaging techniques are fundamental. Breast conserving surgery combined with breast irradiation for patients with invasive and non invasive breast carcinoma has become the treatment of first choice. All surgical conservative approaches should include the complete nipple–areolar complex and margins of resected specimen free of tumor. Thanks to the evolution of the conservative approach, good cosmetic result can be obtained. To be informed about the axillary lymph node status and to avoid the patient to have a second surgical approach, sentinel lymph node biopsy should be performed.
Literature
1.
go back to reference Velpeau A (1856) On disease of the mammary areola preceding cancer of the mammary region (trans: Mitchell H). Sydenham Society, London Velpeau A (1856) On disease of the mammary areola preceding cancer of the mammary region (trans: Mitchell H). Sydenham Society, London
2.
go back to reference Paget J (1874) On disease of the mammary areola preceding carcinoma of the mammary gland. St Bartholomews Hosp Rep 10:87–89 Paget J (1874) On disease of the mammary areola preceding carcinoma of the mammary gland. St Bartholomews Hosp Rep 10:87–89
3.
4.
go back to reference Chaudary MA, Millis RR, Lane EB, Miller NA (1986) Paget’s disease of the nipple: a ten-year review including clinical, pathological, and immunohistochemical findings. Breast Cancer Res Treat 8:139–146PubMedCrossRef Chaudary MA, Millis RR, Lane EB, Miller NA (1986) Paget’s disease of the nipple: a ten-year review including clinical, pathological, and immunohistochemical findings. Breast Cancer Res Treat 8:139–146PubMedCrossRef
5.
go back to reference Dixon AR, Galea MH, Ellis IO, Elston CW, Blamey RW (1991) Paget’s disease of the nipple. Br J Surg 78:722–723PubMedCrossRef Dixon AR, Galea MH, Ellis IO, Elston CW, Blamey RW (1991) Paget’s disease of the nipple. Br J Surg 78:722–723PubMedCrossRef
6.
go back to reference Kothari AS, Beechey-Newman N, Hamed H, Fentiman IS, D’Arrigo C, Hanby AM (2002) Paget disease of the nipple: a multifocal manifestation of higher-risk disease. Cancer 95:1–7PubMedCrossRef Kothari AS, Beechey-Newman N, Hamed H, Fentiman IS, D’Arrigo C, Hanby AM (2002) Paget disease of the nipple: a multifocal manifestation of higher-risk disease. Cancer 95:1–7PubMedCrossRef
7.
go back to reference Fu W, Mittel VK, Young SC (2001) Paget disease of the breast: analysis of 41 patients. Am J Clin Oncol 24:397–400PubMedCrossRef Fu W, Mittel VK, Young SC (2001) Paget disease of the breast: analysis of 41 patients. Am J Clin Oncol 24:397–400PubMedCrossRef
8.
go back to reference Bijker N, Rutgers EJ, Duchateau L, Peterse JL, Julien JP, Cataliotti L et al (2001) Breast-conservating therapy for Paget’s disease of the nipple. Cancer 91:472–477PubMedCrossRef Bijker N, Rutgers EJ, Duchateau L, Peterse JL, Julien JP, Cataliotti L et al (2001) Breast-conservating therapy for Paget’s disease of the nipple. Cancer 91:472–477PubMedCrossRef
9.
go back to reference Muir R (1935) Pathogenesis of Paget’s disease of the nipple and associated lesions. BR J Surg 22:728–737CrossRef Muir R (1935) Pathogenesis of Paget’s disease of the nipple and associated lesions. BR J Surg 22:728–737CrossRef
10.
go back to reference Inglis K (1946) Paget’s disease of the nipple, with special reference to changes in the ducts. Am J Pathol 22:1–33 Inglis K (1946) Paget’s disease of the nipple, with special reference to changes in the ducts. Am J Pathol 22:1–33
11.
go back to reference Yim JH, Wick MR, Philpott GW, Norton JA, Doherty GM (1997) Underlying pathology in mammary Paget’s disease. Ann Surg Oncol 4:287–292PubMedCrossRef Yim JH, Wick MR, Philpott GW, Norton JA, Doherty GM (1997) Underlying pathology in mammary Paget’s disease. Ann Surg Oncol 4:287–292PubMedCrossRef
12.
go back to reference Lagios MD, Westdahl PR, Rose MR, Concannon S (1984) Paget’s disease of the nipple. Alternative management in cases without or with minimal extent of underlying breast carcinoma. Cancer 54:545–551PubMedCrossRef Lagios MD, Westdahl PR, Rose MR, Concannon S (1984) Paget’s disease of the nipple. Alternative management in cases without or with minimal extent of underlying breast carcinoma. Cancer 54:545–551PubMedCrossRef
13.
go back to reference Kollmorgen DR, Varanasi JS, Edge SB, Carson WE III (1998) Paget’s disease of the breast: a 33–year experience. J Am Coll Surg 187:171–177PubMedCrossRef Kollmorgen DR, Varanasi JS, Edge SB, Carson WE III (1998) Paget’s disease of the breast: a 33–year experience. J Am Coll Surg 187:171–177PubMedCrossRef
14.
go back to reference Paone JF, Baker RR (1981) Pathogenesis and treatment of Paget’s disease of the breast. Cancer 48:825–829PubMedCrossRef Paone JF, Baker RR (1981) Pathogenesis and treatment of Paget’s disease of the breast. Cancer 48:825–829PubMedCrossRef
15.
go back to reference Freud H, Maydovnik M, Laufer N, Durst A (1977) Paget’s disease of the breast. J Surg Oncol 9:93–98CrossRef Freud H, Maydovnik M, Laufer N, Durst A (1977) Paget’s disease of the breast. J Surg Oncol 9:93–98CrossRef
16.
go back to reference Kawase K, Dimaio DJ, Tucker SL, Buchholz TA, Ross MI, Feig BW et al (2005) Paget’s disease of the breast: there is a role for breast-conserving therapy. Ann Surg Oncol 1:21–27 Kawase K, Dimaio DJ, Tucker SL, Buchholz TA, Ross MI, Feig BW et al (2005) Paget’s disease of the breast: there is a role for breast-conserving therapy. Ann Surg Oncol 1:21–27
17.
go back to reference Chen C, Sun L, Anderson B (2006) Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the U.S. Cancer 107:1448–1458PubMedCrossRef Chen C, Sun L, Anderson B (2006) Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the U.S. Cancer 107:1448–1458PubMedCrossRef
18.
go back to reference Pierce LJ, Haffty BG, Solin LJ, McCormick B, Vicini FA, Wazer DE et al (1997) The conservative management of Paget’s disease of the breast with radiotherapy. Cancer 80:1065–1072PubMedCrossRef Pierce LJ, Haffty BG, Solin LJ, McCormick B, Vicini FA, Wazer DE et al (1997) The conservative management of Paget’s disease of the breast with radiotherapy. Cancer 80:1065–1072PubMedCrossRef
19.
go back to reference Joseph KA, Ditkoff BA, Estabrook A et al (2007) Therapeutic options for Paget’s disease: a single institution long-term follow-up study. Breast J 13(1):110–111PubMedCrossRef Joseph KA, Ditkoff BA, Estabrook A et al (2007) Therapeutic options for Paget’s disease: a single institution long-term follow-up study. Breast J 13(1):110–111PubMedCrossRef
20.
go back to reference Sukumvanich P, Bentrem DJ, Cody HS et al (2007) The role of sentinel lymph node biopsy in Paget’s disease of the Breast. Ann Surg Oncol 14(3):1020–1023PubMedCrossRef Sukumvanich P, Bentrem DJ, Cody HS et al (2007) The role of sentinel lymph node biopsy in Paget’s disease of the Breast. Ann Surg Oncol 14(3):1020–1023PubMedCrossRef
21.
go back to reference Laronga C, Nasson D, Hoover S et al (2006) Paget’s disease in the era of sentinel lymph node biopsy. Am J Surg 192(4):481–483PubMedCrossRef Laronga C, Nasson D, Hoover S et al (2006) Paget’s disease in the era of sentinel lymph node biopsy. Am J Surg 192(4):481–483PubMedCrossRef
22.
go back to reference Osther PJ, Balslev E, Blichert-Toft M (1990) Paget’s disease of the nipple. Acta Chir Scand 156:343–352PubMed Osther PJ, Balslev E, Blichert-Toft M (1990) Paget’s disease of the nipple. Acta Chir Scand 156:343–352PubMed
23.
go back to reference Jamali FR, Ricci A, Deckers PJ (1970) Paget’s disease of the breast. Am J Surg 76:365–381 Jamali FR, Ricci A, Deckers PJ (1970) Paget’s disease of the breast. Am J Surg 76:365–381
24.
go back to reference Zakaria S, Pantvaidya G, Gosh K, Degnim AC (2007) Paget’s disease of the breast: accuracy of preoperative assessment. Breast Cancer Res Treat 102(2):137–142PubMedCrossRef Zakaria S, Pantvaidya G, Gosh K, Degnim AC (2007) Paget’s disease of the breast: accuracy of preoperative assessment. Breast Cancer Res Treat 102(2):137–142PubMedCrossRef
25.
go back to reference Friedman EP, Hall-Craggs MA, Mumtaz H, Schneidau A (1997) Breast MR and the appearance of the normal and abnormal nipple. Clin Radiol 52:854–861PubMedCrossRef Friedman EP, Hall-Craggs MA, Mumtaz H, Schneidau A (1997) Breast MR and the appearance of the normal and abnormal nipple. Clin Radiol 52:854–861PubMedCrossRef
26.
go back to reference Soderstrom CE, Harms SE, Copit DS et al (1996) 3D RODEO breast MRI of lesions containing ductal carcinoma in situ. Radiology 201:427–432PubMed Soderstrom CE, Harms SE, Copit DS et al (1996) 3D RODEO breast MRI of lesions containing ductal carcinoma in situ. Radiology 201:427–432PubMed
27.
go back to reference Haerslev T, Krag JG (1992) Expression of citokeratin and erbB-2 oncoprotein in Paget’s disease of the nipple. An immunohistochemical study. APMIS 100:1041–1047PubMedCrossRef Haerslev T, Krag JG (1992) Expression of citokeratin and erbB-2 oncoprotein in Paget’s disease of the nipple. An immunohistochemical study. APMIS 100:1041–1047PubMedCrossRef
28.
go back to reference Wolber RA, Dupuis BA, Wick MR (1991) Expression of c-erb-B2 oncoprotein in mammary and extrammamary Paget’s disease. Am J Clin Pathol 96:243–247PubMed Wolber RA, Dupuis BA, Wick MR (1991) Expression of c-erb-B2 oncoprotein in mammary and extrammamary Paget’s disease. Am J Clin Pathol 96:243–247PubMed
29.
go back to reference Lammie GA, Barnes DM, Millis RR, Gullick WJ (1989) An immunohistochemical study of the presence of c-erbB-2 protein in Paget’s disease of the nipple. Histopathology 15:505–514PubMedCrossRef Lammie GA, Barnes DM, Millis RR, Gullick WJ (1989) An immunohistochemical study of the presence of c-erbB-2 protein in Paget’s disease of the nipple. Histopathology 15:505–514PubMedCrossRef
30.
go back to reference Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S et al (1991) The long term significance of c-erB-2 in primary breast cancer. Br J Cancer 63:447–450PubMed Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S et al (1991) The long term significance of c-erB-2 in primary breast cancer. Br J Cancer 63:447–450PubMed
31.
go back to reference McCann AH, Dervan PA, O’Regan M, Codd MB, Gullick WJ, Tobin BM et al (1991) Prognostic significance of c-erbB-2 and oestrogen receptor status in human breast cancer. Cancer Res 51:3296–3303PubMed McCann AH, Dervan PA, O’Regan M, Codd MB, Gullick WJ, Tobin BM et al (1991) Prognostic significance of c-erbB-2 and oestrogen receptor status in human breast cancer. Cancer Res 51:3296–3303PubMed
32.
go back to reference Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R et al (1991) c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63:439–443PubMed Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R et al (1991) c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63:439–443PubMed
33.
go back to reference Polgar C, Orosz Z, Kovacs T, Fodor J (2002) Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer Study of 61 patients. Cancer 94:1904–1905PubMedCrossRef Polgar C, Orosz Z, Kovacs T, Fodor J (2002) Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer Study of 61 patients. Cancer 94:1904–1905PubMedCrossRef
34.
go back to reference Stockdale AD, Brierley JD, White WF, Folkes A, Rostom AY (1989) Radiotherapy for Paget’s disease of the nipple: a conservative alternative. Lancet 2:664–666PubMedCrossRef Stockdale AD, Brierley JD, White WF, Folkes A, Rostom AY (1989) Radiotherapy for Paget’s disease of the nipple: a conservative alternative. Lancet 2:664–666PubMedCrossRef
35.
go back to reference Marshall JK, Griffith KA, Haffty BG, Solin LJ, Vicini FA, McCormick B et al (2003) Conservative management of Paget disease of the breast with radiotherapy: 10- and 15-year outcomes. Cancer 97(9):2142–2149PubMedCrossRef Marshall JK, Griffith KA, Haffty BG, Solin LJ, Vicini FA, McCormick B et al (2003) Conservative management of Paget disease of the breast with radiotherapy: 10- and 15-year outcomes. Cancer 97(9):2142–2149PubMedCrossRef
36.
go back to reference Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation ort he treatment of invasive breast cancer. N Engl J Med 347:1233–1241PubMedCrossRef Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation ort he treatment of invasive breast cancer. N Engl J Med 347:1233–1241PubMedCrossRef
37.
go back to reference Shivers S, Cox C, Leight G et al (2002) Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann Surg Oncol 9:248–255PubMedCrossRef Shivers S, Cox C, Leight G et al (2002) Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann Surg Oncol 9:248–255PubMedCrossRef
38.
go back to reference Lucci A Jr, Kelemen PR 3rd Miller C et al (2001) National practice patterns of sentinel lymph node dissection for breast carcinoma. J Am Coll Surg 192(4):453–458PubMedCrossRef Lucci A Jr, Kelemen PR 3rd Miller C et al (2001) National practice patterns of sentinel lymph node dissection for breast carcinoma. J Am Coll Surg 192(4):453–458PubMedCrossRef
39.
go back to reference Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553PubMedCrossRef Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553PubMedCrossRef
Metadata
Title
Paget’s disease of the breast: the experience of the European institute of oncology and review of the literature
Authors
Mujgan Caliskan
Giovanna Gatti
Irina Sosnovskikh
Nicole Rotmensz
Edoardo Botteri
Simona Musmeci
Gabriela Rosali dos Santos
Giuseppe Viale
Alberto Luini
Publication date
01-12-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9880-5

Other articles of this Issue 3/2008

Breast Cancer Research and Treatment 3/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine